These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Nevitt SJ; Jones AP; Howard J Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137 [TBL] [Abstract][Full Text] [Related]
13. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Wang WC; Dwan K Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646 [TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544 [TBL] [Abstract][Full Text] [Related]
15. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Estcourt LJ; Malouf R; Trivella M; Fergusson DA; Hopewell S; Murphy MF Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011305. PubMed ID: 28128441 [TBL] [Abstract][Full Text] [Related]
16. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617 [TBL] [Abstract][Full Text] [Related]
17. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Radford M; Estcourt LJ; Sirotich E; Pitre T; Britto J; Watson M; Brunskill SJ; Fergusson DA; Dorée C; Arnold DM Cochrane Database Syst Rev; 2024 May; 5(5):CD011305. PubMed ID: 38780066 [TBL] [Abstract][Full Text] [Related]
18. Transfusion thresholds for guiding red blood cell transfusion. Carson JL; Stanworth SJ; Dennis JA; Trivella M; Roubinian N; Fergusson DA; Triulzi D; Dorée C; Hébert PC Cochrane Database Syst Rev; 2021 Dec; 12(12):CD002042. PubMed ID: 34932836 [TBL] [Abstract][Full Text] [Related]
19. Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews. Lewis SR; Pritchard MW; Estcourt LJ; Stanworth SJ; Griffin XL Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013737. PubMed ID: 37294864 [TBL] [Abstract][Full Text] [Related]